Pharma: clinic roundup
Pfizer Inc., of New York, reported that detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults, or CAPiTA, which enrolled approximately 85,000 subjects, demonstrated that Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) prevented a first episode of vaccine-type community-acquired pneumonia (CAP) in adults 65 years of age and older, the study’s primary endpoint. Pfizer said the trial was the first in adults to demonstrate a significant reduction in vaccine-type pneumococcal CAP and non-bacteremic/non-invasive vaccine-type pneumococcal CAP.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter